Inhibitors of NF-κB derived from thalidomide

Bioorganic & Medicinal Chemistry Letters
2007.0

Abstract

A series of compounds originally derived from thalidomide were synthesized and evaluated. The most potent compounds in this series, 5HPP-33 and compound 20, inhibited NF-kappaB activation in HeLa cells. Preliminary study indicated that the mechanism of inhibition of NF-kappaB activation is through inhibition of its translocation from the cytoplasm to the nucleus.

DOI： 10.1016/j.bmcl.2007.01.088

Knowledge Graph

Similar Paper

Inhibitors of NF-κB derived from thalidomide
Bioorganic & Medicinal Chemistry Letters 2007.0
Tubulin-polymerization inhibitors derived from thalidomide
Bioorganic & Medicinal Chemistry Letters 2005.0
Thalidomide analogs and PDE4 inhibition
Bioorganic & Medicinal Chemistry Letters 1998.0
Angiogenesis inhibitors derived from thalidomide
Bioorganic & Medicinal Chemistry Letters 2005.0
Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production
Bioorganic & Medicinal Chemistry Letters 1999.0
Anti-proliferative effect of chalcone derivatives through inactivation of NF-κB in human cancer cells
Bioorganic & Medicinal Chemistry 2014.0
N-phenylsulfonyl-3,5-bis(arylidene)-4-piperidone derivatives as activation NF-κB inhibitors in hepatic carcinoma cell lines
European Journal of Medicinal Chemistry 2018.0
The design and synthesis of novel orally active inhibitors of AP-1 and NF-κB mediated transcriptional activation. SAR of In vitro and In vivo studies
Bioorganic & Medicinal Chemistry Letters 2003.0
Discovery of novel NF-кB inhibitor based on scaffold hopping: 1,4,5,6,7,8-hexahydropyrido[4,3-d]pyrimidine
European Journal of Medicinal Chemistry 2020.0
Development of Novel 1,2,3,4-Tetrahydroquinoline Scaffolds as Potent NF-κB Inhibitors and Cytotoxic Agents
ACS Medicinal Chemistry Letters 2016.0